The program times are listed in Central European Time (CEST)
INDUSTRY SESSION
Date
Fri, 04.06.2021
Session Type
INDUSTRY SESSION
Session Time
17:15 - 18:15
Room
Hall F
Chair(s)
Session Description
Heart failure in Type 2 diabetes – early identification and intervention for improving patient outcome - Independent Medical Education Symposium supported by a unrestricted educational grant from AstraZeneca and Roche Diagnostics
Session description - Learning objectives:
This educational symposium will feature in-depth discussion around:
- The interconnectivity between T2D and HF
- The importance of interdisciplinary collaboration and early intervention in patients with T2D at risk of HF – the viewpoint of a diabetologist and a cardiologist
- The diagnostic role of NT-proBNP in HF in T2D
- The cardiorenal effects of SGLT2 inhibitors in patients with T2D with and without HF or CKD
INDUSTRY SESSION
Heart failure in Type 2 diabetes – early identification and intervention for improving patient outcome
Date
Fri, 04.06.2021
Lecture Time
17:15 - 17:15
INDUSTRY SESSION
Independent Medical Education Symposium supported by a unrestricted educational grant from AstraZeneca and Roche Diagnostics
Date
Fri, 04.06.2021
Lecture Time
17:15 - 17:15
INDUSTRY SESSION
Welcome and Introduction
Date
Fri, 04.06.2021
Lecture Time
17:15 - 17:20
Presenter
Authors
INDUSTRY SESSION
HF in T2D: perspectives from a diabetologist and a cardiologist
Date
Fri, 04.06.2021
Lecture Time
17:20 - 17:40
INDUSTRY SESSION
NT-proBNP - the gold standard biomarker for screening and diagnosis of HF
Date
Fri, 04.06.2021
Lecture Time
17:40 - 17:50
INDUSTRY SESSION
Time to act - SGLT2 inhibitors in HF
Date
Fri, 04.06.2021
Lecture Time
17:50 - 18:00
Presenter
Authors
INDUSTRY SESSION
Time to act - SGLT2 inhibitors in HF Panel discussion and Q&A
Date
Fri, 04.06.2021
Lecture Time
18:00 - 18:15